<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711409741</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711409741</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of Endothelial Nitric Oxide Synthase Gene Variant (G894T) With Coronary Artery Disease in Western Iran</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rahimi</surname>
<given-names>Zohreh</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409741">1</xref>
<xref ref-type="aff" rid="aff2-0003319711409741">2</xref>
<xref ref-type="corresp" rid="corresp1-0003319711409741"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nourozi-Rad</surname>
<given-names>Reza</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff2-0003319711409741">2</xref>
<xref ref-type="aff" rid="aff3-0003319711409741">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711409741"><label>1</label>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff>
<aff id="aff2-0003319711409741"><label>2</label>Department of Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff>
<aff id="aff3-0003319711409741"><label>3</label>Department of Biochemistry, Medical School, Ahvaz University of Medical Sciences, Ahvaz, Iran</aff>
<author-notes>
<corresp id="corresp1-0003319711409741">Zohreh Rahimi, Medical Biology Research Center, Medical School, Daneshgah Avenue, Kermanshah, PO Box 67148-69914, Iran Email:<email>zrahimi@kums.ac.ir</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>137</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>There are conflicting reports about the association of endothelial nitric oxide synthase (eNOS) gene polymorphism and the risk of coronary artery disease (CAD). To determine the frequency of eNOS G894T variant and to find the possible association between this polymorphism with CAD we studied 207 unrelated patients with total CAD (with and without diabetes) and 92 controls. The eNOS variants were detected by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). The presence of GT + TT genotype was associated with 2.1-fold (<italic>P</italic> = .006), 2.29-fold (<italic>P</italic> = .006), and 1.93-fold (<italic>P</italic> = .032) increased risk of CAD in total CAD, CAD with diabetes, and in CAD without diabetes patients, respectively. The presence of T allele of eNOS increased the risk of CAD 2.15-fold (<italic>P</italic> = .001). The levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) tended to be higher in patients carrier for T allele compared to those with G allele. The results of present study revealed that eNOS G894T polymorphism is associated with increased risk of CAD in our population.</p>
</abstract>
<kwd-group>
<kwd>eNOS G894T</kwd>
<kwd>coronary artery disease</kwd>
<kwd>lipids</kwd>
<kwd>Western Iran</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711409741">
<title>Introduction</title>
<p>High prevalence of coronary artery disease (CAD) risk factors has been reported among Iranians.<sup><xref ref-type="bibr" rid="bibr1-0003319711409741">1</xref></sup> Coronary artery disease is a multifactorial disorder resulting from gene–environmental interaction.<sup><xref ref-type="bibr" rid="bibr2-0003319711409741">2</xref></sup></p>
<p>Nitric oxide synthase (NOS) catalyzes the oxidation of L-arginine to L-citrulline producing NO which is an important regulator of vasodilator tone and blood pressure.<sup><xref ref-type="bibr" rid="bibr3-0003319711409741">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319711409741">4</xref></sup> Functionally important variants of endothelial NOS (eNOS), 1 of the 3 isoforms of NOS, contribute to endothelial dysfunction and attenuate the NO production by the endothelium which could influence individual susceptibility to atherosclerosis.<sup><xref ref-type="bibr" rid="bibr3-0003319711409741">3</xref>,<xref ref-type="bibr" rid="bibr5-0003319711409741">5</xref></sup> The G894T polymorphism of eNOS resulting from G to T conversion at nucleotide 894 of exon 7 of the gene is one of the most clinically important polymorphisms of eNOS. It has been suggested that in the presence of eNOS TT genotype, there is a significant decrease in the amount of eNOS or its enzymatic activity<sup><xref ref-type="bibr" rid="bibr5-0003319711409741">5</xref>,<xref ref-type="bibr" rid="bibr6-0003319711409741">6</xref></sup> and the eNOS Asp298 protein has enhanced susceptibility to intracellular proteolytic cleavage compared with the eNOS Glu298 protein<sup><xref ref-type="bibr" rid="bibr6-0003319711409741">6</xref>,<xref ref-type="bibr" rid="bibr7-0003319711409741">7</xref></sup> resulting in reduced NO level.<sup><xref ref-type="bibr" rid="bibr3-0003319711409741">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319711409741">4</xref></sup></p>
<p>There are controversial results related to the role of eNOS G894T on the predisposition to CAD. In some populations including American,<sup><xref ref-type="bibr" rid="bibr6-0003319711409741">6</xref></sup> British,<sup><xref ref-type="bibr" rid="bibr8-0003319711409741">8</xref></sup> Japanese,<sup><xref ref-type="bibr" rid="bibr9-0003319711409741">9</xref>,<xref ref-type="bibr" rid="bibr10-0003319711409741">10</xref></sup> Taiwanese,<sup><xref ref-type="bibr" rid="bibr11-0003319711409741">11</xref></sup> Turkish,<sup><xref ref-type="bibr" rid="bibr12-0003319711409741">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319711409741">13</xref></sup> Tunisian,<sup><xref ref-type="bibr" rid="bibr14-0003319711409741">14</xref></sup> Egyptian,<sup><xref ref-type="bibr" rid="bibr15-0003319711409741">15</xref></sup> and Hungarians<sup><xref ref-type="bibr" rid="bibr16-0003319711409741">16</xref></sup> association between Glu298Asp polymorphism with the occurrence of CAD or myocardial infarction (MI) have been reported. On the other hand, other studies from Italian,<sup><xref ref-type="bibr" rid="bibr17-0003319711409741">17</xref></sup> Australian,<sup><xref ref-type="bibr" rid="bibr18-0003319711409741">18</xref>,<xref ref-type="bibr" rid="bibr19-0003319711409741">19</xref></sup> Chilean,<sup><xref ref-type="bibr" rid="bibr20-0003319711409741">20</xref></sup> Korean,<sup><xref ref-type="bibr" rid="bibr21-0003319711409741">21</xref></sup> Indian,<sup><xref ref-type="bibr" rid="bibr22-0003319711409741">22</xref></sup> Canadian,<sup><xref ref-type="bibr" rid="bibr23-0003319711409741">23</xref></sup> Turkish,<sup><xref ref-type="bibr" rid="bibr24-0003319711409741">24</xref></sup> and Greece<sup><xref ref-type="bibr" rid="bibr25-0003319711409741">25</xref></sup> failed to detect any relationship between this polymorphism and the risk of atherosclerosis.</p>
<p>Previously, we indicated that the presence of GT + TT genotype of eNOS was associated with significantly increased risk of CAD in type 2 diabetes mellitus (T2DM) patients with macroalbuminuria compared to patients with normoalbuminuria having the same genotype.<sup><xref ref-type="bibr" rid="bibr26-0003319711409741">26</xref></sup> Regarding the controversial reports related to the influence of eNOS variants on the predisposition to CAD, the aim of present study was to detect the frequency of these variants among patients with CAD and controls to find whether there is possible association between this polymorphism and the risk of CAD among population from Western Iran.</p>
</sec>
<sec id="section2-0003319711409741">
<title>Materials and Methods</title>
<p>Participants were those who were referred to the Cardiology Division of the Imam Ali Hospital of the Kermanshah University of Medical Sciences to undergo their first coronary angiography to evaluate the presence and extent of CAD. Patients undergoing coronary angiography for conditions such as valvular or congenital heart disease and restrictive or dilated cardiomyopathy were excluded. Only patients undergoing elective angiography were included in order to avoid the influence of stress situations. There were 207 patients with CAD including 113 males and 94 females with the mean age of 56.9 ± 8.6 years. The total CAD group consisted of 102 patients with CAD having T2DM including 52 males and 50 females aged 57.6 ± 8.8 years and 105 patients with CAD without T2DM including 61 males and 44 females aged 55.8 ± 9.4 years. The male and female patients were selected to be sex- and age-matched with controls. The controls were 92 unrelated participants (47 males and 45 females with the mean age of 54.3 ± 8.5 years). The controls consisted of nondiabetic individuals who were evaluated by angiography for suspected CAD but had normal coronary arteries (with no history of diabetes according to fasting blood sugar). Coronary angiograms were obtained with the Judkins percutaneous retrograde femoral artery technique<sup><xref ref-type="bibr" rid="bibr27-0003319711409741">27</xref></sup> using Phillips Diagnost 5 and 35 mm films (filmed at 25 frames) supplied from Germany. All films were reviewed by 2 cardiologists with no prior knowledge of the condition of the patients. Coronary artery involvement was defined as ≥50% diameter obstruction of a major coronary vessel. All patients and controls were recruited from Imam Ali Hospital of Kermanshah University of Medical Sciences and were from Western population of Iran with Kurdish ethnic background. The diagnosis of diabetes in patients was confirmed using WHO criteria.<sup><xref ref-type="bibr" rid="bibr28-0003319711409741">28</xref></sup> Informed written consent was obtained from each individual before participation in the study. The study was approved by the Ethics Committee of Kermanshah University of Medical Sciences and was in accordance with the principles of the Declaration of Helsinki II.</p>
<sec id="section3-0003319711409741">
<title>DNA Analysis</title>
<p>DNA was extracted from leukocytes of whole blood by phenol–chloroform method.<sup><xref ref-type="bibr" rid="bibr29-0003319711409741">29</xref></sup> To amplify a region in exon 7 of eNOS gene containing G894T polymorphism, 2 primers of forward 5’-AAG GCA GGA GAC AGT GGA TGG A-3’ and reverse 5’-CCC AGT CAA TCC CTT TGG TGC TCA-3’ were used.<sup><xref ref-type="bibr" rid="bibr4-0003319711409741">4</xref></sup> After amplification the polymerase chain reaction (PCR) products were digested by 5 units restriction endonuclease of <italic>Mbo</italic>I for overnight at 37°C. The genotyping of the eNOS gene was determined by fragment separation on a 3.0% agarose gel. The GG, GT, and TT genotypes of <italic>Mbo</italic>I restricted products of eNOS G894T had band sizes of 248 bp, 248 bp/158 bp/90 bp, and 158 bp/90 bp, respectively.</p>
</sec>
<sec id="section4-0003319711409741">
<title>Chemical Analysis</title>
<p>Total plasma cholesterol (TC) and triglycerides (TG) were measured by the standard enzymatic method (Pars Azmon kit, Iran), using an automated RA-1000 (Technicon, USA). The plasma low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured using commercially available enzyme assay kits (Pars Azmon kit).</p>
</sec>
<sec id="section5-0003319711409741">
<title>Statistical Analysis</title>
<p>The allelic frequencies were calculated by the chromosome counting method. The genotypes and eNOS allele frequencies in patients with CAD were compared to controls and the significance of differences calculated using χ<sup>2</sup> test. Odds ratios (ORs) were calculated as estimates of relative risk of disease, and 95% confidence intervals (CI) obtained by SPSS logistic regression software. The correlation values of plasma HDL-C, LDL-C, TG, and total cholesterol (TC) level with the eNOS polymorphism between patients and controls were calculated using linear regression and an unpaired <italic>t</italic> test. A 2-tailed student <italic>t</italic> test was used to compare quantitative data. Statistical significance was assumed at the <italic>P</italic> &lt; .05 level. The SPSS statistical software package version 11.5 was used for the statistical analysis.</p>
</sec>
</sec>
<sec id="section6-0003319711409741">
<title>Results</title>
<p>Demographic and biochemical characteristics of patients and controls are shown in <xref ref-type="table" rid="table1-0003319711409741">Table 1</xref>. The levels of TG, TC, and LDL-C were significantly higher and HDL-C concentration was significantly lower in patients with CAD compared to controls. The distribution of eNOS genotypes and alleles are demonstrated in <xref ref-type="table" rid="table2-0003319711409741">Table 2</xref>
. In the recessive genetic model to evaluate the risk effect of eNOS G894T on CAD, we combined the TT and GT genotypes and compared GT + TT with GG genotype, according to Zintzaras et al.<sup><xref ref-type="bibr" rid="bibr30-0003319711409741">30</xref></sup></p>
<table-wrap id="table1-0003319711409741" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic Characteristics and Distribution of Risk Factors in CAD Patients and Controls
<sup><xref ref-type="table-fn" rid="table-fn2-0003319711409741">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319711409741" xlink:href="10.1177_0003319711409741-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th align="center">CAD Patients (n = 207)</th>
<th align="center">Controls (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56.9 ± 8.6 NS<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409741">b</xref></sup>
</td>
<td>54.3 ± 8.5</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>113/94 (54.6/45.4%) NS<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409741">b</xref></sup>
</td>
<td>47/45 (51.1/48.9%)</td>
</tr>
<tr>
<td>FBS (mg/dL)</td>
<td>136.2 ± 59.6, <italic>P</italic> &lt; .001</td>
<td>97.0 ± 20.1</td>
</tr>
<tr>
<td>History of hypertension (%)</td>
<td>102 (49.6), <italic>P</italic> &lt; .001</td>
<td>24 (26.1)</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>96 ± 28, <italic>P</italic> &lt; .001</td>
<td>83 ± 18</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>47 ± 9.3, <italic>P</italic> = .007</td>
<td>49.8 ± 5.8</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>186 ± 42, <italic>P</italic> = 0.046</td>
<td>177 ± 26</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>177 ± 89, <italic>P</italic> = .038</td>
<td>156 ± 48</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>26 ± 2.7 NS<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409741">b</xref></sup>
</td>
<td>26.6 ± 3.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711409741">
<p>Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein-cholesterol, TC, total cholesterol, TG, triglycerides; FBS, fasting blood sugar.</p>
</fn>
<fn id="table-fn2-0003319711409741">
<p>
<sup>a</sup> Plasma LDL-C, HDL-C, TC, TG, and FBS levels and also age and body mass index (BMI) were compared between patients and controls using 2-tailed Student <italic>t</italic> test. The sex was compared between 2 groups by the χ<sup>2</sup> test.</p>
</fn>
<fn id="table-fn3-0003319711409741">
<p>
<sup>b</sup> NS not significant (<italic>P</italic> &gt; .05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319711409741" position="float">
<label>Table 2.</label>
<caption>
<p>The Distribution of eNOS Genotypes and Alleles in Patients With CAD and in Controls</p>
</caption>
<graphic alternate-form-of="table2-0003319711409741" xlink:href="10.1177_0003319711409741-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Patients With CAD (n = 207)</th>
<th>CAD with T2DM (n = 102)</th>
<th>CAD without T2DM (n = 105)</th>
<th>Controls (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">eNOS genotypes</td>
</tr>
<tr>
<td> GG</td>
<td>116 (56%)</td>
<td>55 (53.9%)</td>
<td>61 (58.1%)</td>
<td>67 (72.8%)</td>
</tr>
<tr>
<td> GT + TT</td>
<td>91 (44%)</td>
<td>47 (46.1%)</td>
<td>44 (41.9%)</td>
<td>25 (27.2%)</td>
</tr>
<tr>
<td>
</td>
<td align="center">(χ<sup>2</sup> = 7.6, <italic>df</italic> = 1, <italic>P</italic> = .006)<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td align="center">(χ<sup>2</sup> = 7.4, <italic>df</italic> = 1, <italic>P</italic> = .006)<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td align="center">(χ<sup>2</sup> = 4.7, <italic>df</italic> = 1, <italic>P</italic> = .031)<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="5">eNOS alleles</td>
</tr>
<tr>
<td> G</td>
<td>306 (73.9%)</td>
<td>151 (74%)</td>
<td>155 (73.8%)</td>
<td>158 (85.9%)</td>
</tr>
<tr>
<td> T</td>
<td>108 (26.1%)</td>
<td>53 (26%)</td>
<td>55 (26.2%)</td>
<td>26 (14.1%)</td>
</tr>
<tr>
<td>
</td>
<td align="center">(χ<sup>2</sup> = 10.5, <italic>df</italic> = 1, <italic>P</italic> = .001)<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td align="center">(χ<sup>2</sup> = 8.4, <italic>df</italic> = 1, <italic>P</italic> = .004)<sup>
<xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td align="center">(χ<sup>2</sup> = 8.7, <italic>df</italic> = 1, <italic>P</italic> = .003)<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409741">a</xref></sup>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0003319711409741">
<p>Abbreviations: eNOS, endothelial nitric oxide synthase; CAD, coronary artery disease; T2DM, type 2 diabetes mellitus.</p>
</fn>
<fn id="table-fn5-0003319711409741">
<p>
<sup>a</sup> The distribution of alleles and genotypes frequencies of eNOS in patients with CAD compared with controls were calculated using χ<sup>2</sup> test analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The frequency of GT + TT genotype (44%) was significantly (<italic>P</italic> = .006) higher in total CAD patients compared to controls (27.2%). In CAD patients with and without diabetes, these frequencies were 46.1% and 41.9%, respectively (<italic>P</italic> = .006 and <italic>P</italic> = .031, respectively). The frequencies of T allele in total CAD, CAD with T2DM, CAD without T2DM, and in control groups were 26.1%, 26%, 26.2%, and 14.1%, respectively (<italic>P</italic> = .001, .004, and 0.003, respectively). The presence of GT + TT genotype was associated with 2.1-fold (95%CI 1.23-3.6, <italic>P</italic> = .006), 2.29-fold (95%CI 1.25-4.2, <italic>P</italic> = .006), and 1.93-fold (95%CI 1.1-3.5, <italic>P</italic> = .032) increased risk of CAD in total CAD, CAD patients with T2DM, and in CAD patients without diabetes, respectively. In total CAD, CAD patients with T2DM, and CAD patients without diabetes groups, the T allele of eNOS increased the risk of CAD 2.15-fold (<italic>P</italic> = .001), 1.46-fold (95% CI 1.13-1.9, <italic>P</italic> = .004), and 2.16-fold (<italic>P</italic> = .004), respectively, as indicated in <xref ref-type="table" rid="table3-0003319711409741">Table 3</xref>. Adjusted logistic regression analysis for the effects of age, sex, hypertension, diabetes, and hyperlipidemia was performed. The T allele of eNOS increased the risk of CAD 1.5 times, which did not reach to a statistical significant (<xref ref-type="table" rid="table4-0003319711409741">Table 4</xref>).</p>
<table-wrap id="table3-0003319711409741" position="float">
<label>Table 3.</label>
<caption>
<p>Odds Ratios of eNOS Genotypes and Alleles With Respect to GG Genotype or G Allele in Patients With CAD
<sup><xref ref-type="table-fn" rid="table-fn7-0003319711409741">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0003319711409741" xlink:href="10.1177_0003319711409741-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Patients With CAD (n = 207) ORs (95% CI)</th>
<th>CAD With T2DM (n = 102) ORs (95% CI)</th>
<th>CAD Without T2DM (n = 105) ORs (95% CI)</th>
<th>Controls (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">eNOS genotypes</td>
</tr>
<tr>
<td> GG</td>
<td>Reference group (n = 116)</td>
<td>Reference group (n = 55)</td>
<td>Reference group (n = 61)</td>
<td>Referent group (n = 67)</td>
</tr>
<tr>
<td> GT + TT</td>
<td>2.1 (1.23- 3.6, <italic>P</italic> = .006, n = 91)</td>
<td>2.29 (1.25-4.2, <italic>P</italic> = .006, n = 47)</td>
<td>1.93 (1.1-3.5, <italic>P</italic> = 0.031, n = 44)</td>
<td>n = 25</td>
</tr>
<tr>
<td colspan="5">eNOS alleles</td>
</tr>
<tr>
<td> G</td>
<td>Reference group (n = 306)</td>
<td>Reference group (n = 151)</td>
<td>Reference group (n = 155)</td>
<td>Referent group (n = 158)</td>
</tr>
<tr>
<td> T</td>
<td>2.15 (1.4-3.5, <italic>P</italic> = .001, n = 108)</td>
<td>1.46 (1.13-1.9, <italic>P</italic> = 0.004, n = 53)</td>
<td>2.16 (1.3-3.6, <italic>P</italic> = .004, n = 55)</td>
<td>n = 26</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0003319711409741">
<p>Abbreviations: eNOS, endothelial nitric oxide synthase; CAD, coronary artery disease; T2DM, type 2 diabetes mellitus.</p>
</fn>
<fn id="table-fn7-0003319711409741">
<p>
<sup>a</sup> Odds ratios (ORs) as estimate of relative risk for disease were calculated and 95% confidence intervals were obtained using χ<sup>2</sup> regression binary logistic analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0003319711409741" position="float">
<label>Table 4.</label>
<caption>
<p>The Odd Ratios of eNOS Alleles With Respect to G Allele in Patients With CAD and in Controls After Adjusting for Sex, Age, Normolipidemia, Absence History of Diabetes and Hypertension
<sup><xref ref-type="table-fn" rid="table-fn9-0003319711409741">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-0003319711409741" xlink:href="10.1177_0003319711409741-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Patients With CAD or (95%CI)</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">eNOS alleles In normolipidemia, no history of diabetes and hypertension</td>
</tr>
<tr>
<td> G</td>
<td>Reference group (n = 85, 81.7%)</td>
<td>Reference group (n = 51, 75%)</td>
</tr>
<tr>
<td> T</td>
<td>1.5 (0.71-3.2, <italic>P</italic> = .29, n = 19, 18.3%)</td>
<td>n = 17, 25%</td>
</tr>
<tr>
<td>
</td>
<td>χ<sup>2</sup> = 1.2, <italic>df</italic> = 1, <italic>P</italic> = 0.2</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0003319711409741">
<p>Abbreviations: eNOS, endothelial nitric oxide synthase; CAD, coronary artery disease.</p></fn>
 <fn id="table-fn9-0003319711409741">
<p>
<sup>a</sup> Odds ratios (ORs) as an estimate of relative risk for disease was calculated and 95% confidence intervals were obtained using χ<sup>2</sup> regression binary logistic analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>in <xref ref-type="table" rid="table5-0003319711409741">Table 5</xref>, the plasma levels of TG, TC, LDL-C, and HDL-C were compared between patients and controls with G and T alleles. Total CAD, CAD with T2DM, and CAD without T2DM with T or G allele had significantly higher levels of LDL-C compared to controls with the same alleles. High-density lipoprotein cholesterol level in the presence of T allele in total CAD and CAD patients with T2DM was significantly (<italic>P</italic> = .007 and <italic>P</italic> &lt; .001, respectively) lower than controls with the same allele. The level of TC was significantly (<italic>P</italic> = .016 and <italic>P</italic> = .004, respectively) higher in total CAD and CAD with T2DM groups with G allele compared to the control group with the same allele. When lipids levels in the carriers of T allele were compared to those with G allele in each group of patients, we found that LDL-C and TG levels tended to be higher in total CAD and CAD without T2DM patients carrier for T allele compared to patient carriers of G allele (<xref ref-type="table" rid="table5-0003319711409741">Table 5</xref>). In CAD with T2DM group, only LDL-C was nonsignificantly higher in carriers of T allele compared to those patients with G allele. In contrast, in the presence of T allele, the level of TG tended to be lower compared to the presence of G allele in CAD patients with T2DM. Also, the level of TG was significantly higher in CAD patients with T2DM carriers of G or T allele compared to controls with the same alleles as indicated in <xref ref-type="table" rid="table5-0003319711409741">Table 5</xref>.</p>
<table-wrap id="table5-0003319711409741" position="float">
<label>Table 5.</label>
<caption>
<p>Comparison of LDL-C, HDL-C, TC, and TG Levels Between eNOS Genotypes (GG, GT + TT) and Alleles in Patients With CAD and in Controls
<sup><xref ref-type="table-fn" rid="table-fn11-0003319711409741">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table5-0003319711409741" xlink:href="10.1177_0003319711409741-table5.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">CAD without T2DM</th>
<th align="center">CAD with T2DM</th>
<th align="center">Total CAD</th>
<th align="center">Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>n = 61</td>
<td>n = 55</td>
<td>n = 116</td>
<td>n = 67</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>91.5 ± 23.2 (<italic>P</italic> = .58)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>97.8 ± 31.3 (<italic>P</italic> = .003)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>94.5 ± 27.4 (<italic>P</italic> = 0.006)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>84 ± 17.5</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>49.1 ± 6.8 (<italic>P</italic> = .24)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>44.6 ± 12.1 (<italic>P</italic> = .006)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>47 ± 9.9 (<italic>P</italic> = .1)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>49.1 ± 4.7</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>182 ± 33 (<italic>P</italic> = .44)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>192.4 ± 51.2 (<italic>P</italic> = .06)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>187 ± 42.5 (<italic>P</italic> = .16)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>179 ± 26</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>146 ± 73 (<italic>P</italic> = .26)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>212 ± 94.6 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>177 ± 90 (<italic>P</italic> = .1)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>165 ± 71</td>
</tr>
<tr>
<td>GT + TT</td>
<td>n = 44</td>
<td>n = 47</td>
<td>n = 91</td>
<td>n = 25</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>97.8 ± 29.3 (<italic>P</italic> = .002)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .22<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>97.7 ± 30.5 (<italic>P</italic> = .007)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = 0.9<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>98 ± 30 (<italic>P</italic> = .004)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .41<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td align="center">79.2 ± 18.5; <italic>P</italic> = .23<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>49.2 ± 8.4 (<italic>P</italic> = .34)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .95<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>44.9 ± 8.5 (<italic>P</italic> = .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .8<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>47 ± 8.7 (<italic>P</italic> = .013)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = 0.98<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>51.8 ± 7.7; <italic>P</italic> = .040<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c
</xref></sup>
</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>184 ± 41 (<italic>P</italic> = .28)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .82<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>187 ± 43.9 (<italic>P</italic> = .09)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .57<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>185 ± 42 (<italic>P</italic> = .1)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .78<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>171 ± 26; <italic>P</italic> = .19<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c
</xref></sup>
</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>160 ± 96 (<italic>P</italic> = .95)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .38<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>191 ± 78.9 (<italic>P</italic> = .26)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .22<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>176 ± 88 (<italic>P</italic> = .18)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .91<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup></td>
<td>152 ± 44; <italic>P</italic> = .6<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup></td>
</tr>
<tr>
<td>G allele</td>
<td>n = 155</td>
<td>n = 151</td>
<td>n = 306</td>
<td>n = 158</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>93.2 ± 25 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>97.3 ± 3 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>95.2 ± 28.1 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>83.4 ± 17.7</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>49.2 ± 7.2 (<italic>P</italic> = .69)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>44.7 ± 11.2 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>47 ± 9.7 (<italic>P</italic> = .003)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>49.5 ± 5.3</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>182 ± 33.3 (<italic>P</italic> = .16)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>191 ± 49.5 (<italic>P</italic> = .004)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>187 ± 42.2 (<italic>P</italic> = .016)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup></td>
<td>178 ± 25.9</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>147 ± 76.6 (<italic>P</italic> = .05)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>205 ± 90.4 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>176 ± 88.4 (<italic>P</italic> = .11)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>
</td>
<td>163 ± 67.1</td>
</tr>
<tr>
<td>T allele</td>
<td>n = 55</td>
<td>n = 53</td>
<td>n = 108</td>
<td>n = 26</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>96.7 ± 28.6 (<italic>P</italic> = .005)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .39<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>99.1 ± 30.1 (<italic>P</italic> = 0.002)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .7<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>97.9 ± 29.3 (<italic>P</italic> = .002)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .4<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>78.9 ± 18.2; <italic>P</italic> = .22<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>49.1 ± 8.2 (<italic>P</italic> = .12)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .93<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>44.9 ± 8.2 (<italic>P</italic> &lt; .001)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .8<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>47.1 ± 8.4 (<italic>P</italic> = .007)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .93<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>52.1 ± 7.6; <italic>P</italic> = .034<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>184 ± 43.3 (<italic>P</italic> =.17)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .77<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>187.7 ± 42.3 (<italic>P</italic> =.078)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .6<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>186 ± 42.6 (<italic>P</italic> = .1)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .88<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>172 ± 25.2; <italic>P</italic> = .27<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>164 ± 98.6 (<italic>P</italic> = .49)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .19<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>193.6 ± 79.8 (<italic>P</italic> = .013)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> = .4<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>179 ± 90.6 (<italic>P</italic> = .12)<sup><xref ref-type="table-fn" rid="table-fn12-0003319711409741">b</xref></sup>; <italic>P</italic> =.77<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
<td>151 ± 43.3; <italic>P</italic> = .36<sup><xref ref-type="table-fn" rid="table-fn13-0003319711409741">c</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0003319711409741">
<p>Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein-cholesterol, TC, total cholesterol, TG, triglycerides.</p>
</fn>
<fn id="table-fn11-0003319711409741">
<p>
<sup>a</sup> The correlation values of plasma HDL-C, LDL-C, TG, and TC levels with eNOS polymorphism between patients and controls were calculated using <italic>t</italic> test analysis.</p>
</fn>
<fn id="table-fn12-0003319711409741">
<p>
<sup>b</sup> Comparison has been made between patients and controls.</p>
</fn>
<fn id="table-fn13-0003319711409741">
<p>
<sup>c</sup> Comparisons have been made within each group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0003319711409741">
<title>Discussion</title>
<p>Atheroprotective role of NO has been suggested through its role in the relaxation of vascular smooth muscle, inhibition of adhesion of platelets and leukocytes to the endothelium, reduction in the migration of vascular smooth muscle cells, and proliferation and limitation of the LDL-C oxidation.<sup><xref ref-type="bibr" rid="bibr20-0003319711409741">20</xref>
</sup> Endothelial dysfunction is a component of CAD and its prognosis. A hallmark of endothelial dysfunction is the reduced level of NO.<sup><xref ref-type="bibr" rid="bibr31-0003319711409741">31</xref></sup></p>
<p>In the present study, we observed an association between the T allele of eNOS G894T and the risk of CAD in coronary artery disease patients with and without T2DM. There are conflicting results related to the role of eNOS variants on the risk of CAD in various populations. The meta-analysis of Casas et al<sup><xref ref-type="bibr" rid="bibr32-0003319711409741">32</xref></sup> included 23 028 patients who indicated homozygosity for T allele moderately increased the risk of ischemic heart disease. Also, the recent meta-analysis of Li et al<sup><xref ref-type="bibr" rid="bibr33-0003319711409741">33</xref></sup> including 23 studies for eNOS G894T indicated that this polymorphism is associated with the risk of CAD. Gulec et al<sup><xref ref-type="bibr" rid="bibr34-0003319711409741">34</xref></sup> in a cohort study of 473 consecutive patients with high-grade coronary artery stenosis or occlusion reported a significant association between this polymorphism and impaired collateral development, especially in patients with diabetes mellitus. Odeberg et al<sup><xref ref-type="bibr" rid="bibr35-0003319711409741">35</xref></sup> have shown a strong association between eNOS Glu298Asp genotype and acute MI (AMI) in patients with T2DM. Among US diabetic men, the eNOS polymorphism was potentially associated with coronary heart disease (CHD) through significant elevation in the endothelial dysfunction markers of soluble vascular cell adhesion molecule (sVCAM) and soluble intercellular cell adhesion molecule (sICAM-1).<sup><xref ref-type="bibr" rid="bibr6-0003319711409741">6</xref></sup> It has been suggested that endothelial dysfunction and vascular inflammation contribute to the accelerated atherogenesis associated with T2DM.<sup><xref ref-type="bibr" rid="bibr6-0003319711409741">6</xref></sup> The association between this polymorphism and the risk of CAD and MI in the UK patients<sup><xref ref-type="bibr" rid="bibr8-0003319711409741">8</xref></sup> compared to controls have been reported. Szbo et al.<sup><xref ref-type="bibr" rid="bibr16-0003319711409741">16</xref></sup> from Hungry reported that eNOS G894T polymorphism was a major risk factor for carotid artery disease and MI. The frequency of T allele of eNOS in Asian has significantly been lower (7.6%) than that in non-Asians (32%).<sup><xref ref-type="bibr" rid="bibr32-0003319711409741">32</xref></sup> Among Asian populations, there are reports of association between this polymorphism and the risk of CAD. In Taiwanese, the frequency of the G894T polymorphism of the <italic>eNOS</italic> gene was significantly different between control participants and patients with coronary vascular disease (CVD), which suggested that this polymorphism is likely to be a risk factor for CVD in the eastern Taiwanese population.<sup><xref ref-type="bibr" rid="bibr11-0003319711409741">11</xref></sup> Among Japanese diabetic patients, the polymorphism of G894T was significantly associated with ischemic heart disease.<sup><xref ref-type="bibr" rid="bibr10-0003319711409741">10</xref></sup> In their study, the HDL-C level was marginally lower in individuals with GT or TT genotypes compared to those with GG genotype. An HDL-mediated increase in eNOS activity has been suggested.<sup><xref ref-type="bibr" rid="bibr36-0003319711409741">36</xref>,<xref ref-type="bibr" rid="bibr37-0003319711409741">37</xref></sup> In a separate study by Japan Shimaski et al,<sup><xref ref-type="bibr" rid="bibr9-0003319711409741">9</xref></sup> a significantly higher frequency of T allele of eNOS in Japanese patients with MI was reported. Also, in 2 separate studies from Turkey association between eNOS G894T polymorphism and premature coronary artery disease has been demonstrated.<sup><xref ref-type="bibr" rid="bibr12-0003319711409741">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319711409741">13</xref></sup> Kerkeni et al.<sup><xref ref-type="bibr" rid="bibr14-0003319711409741">14</xref></sup> among Tunisian population reported an association between eNOS G894T polymorphism and the presence of CAD. Nagib El-kilany et al<sup><xref ref-type="bibr" rid="bibr39-0003319711409741">39</xref></sup> observed a strong association between Glu298Asp polymorphism (homozygote Asp) with ischemic heart disease and isolated hypertension. The study by Motawi et al<sup><xref ref-type="bibr" rid="bibr15-0003319711409741">15</xref></sup> from Egypt suggested that homozygosity for G894T polymorphism may predispose to CAD. In agreement with these reports, we observed that the T allele of eNOS significantly increased the risk of CAD 2.15-fold. However, several studies reported the absence of association between eNOS Glu298Asp polymorphism with CAD and MI. Aras et al<sup><xref ref-type="bibr" rid="bibr24-0003319711409741">24</xref></sup> among a population from Turkey observed the lack of association between eNOS G894T polymorphism and the risk of CAD and MI. The similar results obtained by Nasser et al<sup><xref ref-type="bibr" rid="bibr23-0003319711409741">23</xref></sup> indicated no contribution of this polymorphism on the development of premature CAD. Also, in a study of general population, Karvonen et al<sup><xref ref-type="bibr" rid="bibr38-0003319711409741">38</xref></sup> reported that eNOS G894T might not be a major risk factor for cardiovascular events. Further, Cai et al<sup><xref ref-type="bibr" rid="bibr18-0003319711409741">18</xref></sup> and Liyou et al<sup><xref ref-type="bibr" rid="bibr19-0003319711409741">19</xref></sup> did not detect an association between eNOS G894T polymorphism and CAD among Australians. In agreement with the above-mentioned studies, Brscic et al<sup><xref ref-type="bibr" rid="bibr17-0003319711409741">17</xref></sup> did not demonstrate an association between this polymorphism and recurrent events of MI after a primary MI among young Italian patients. In a relatively large-scale study of Greek population, Andrikopoulos et al<sup><xref ref-type="bibr" rid="bibr25-0003319711409741">25</xref></sup> observed no association between the risk of MI, extent of CAD, and in-hospital mortality after MI with eNOS G894T polymorphism. A similar frequency of eNOS genotypes in CAD or MI patients compared to controls from Taiwan has been reported by Wang et al.<sup><xref ref-type="bibr" rid="bibr40-0003319711409741">40</xref></sup> Further, the absence of association between the risk of CAD and the presence of this polymorphism has been found among Indian,<sup><xref ref-type="bibr" rid="bibr22-0003319711409741">22</xref></sup> Korean,<sup><xref ref-type="bibr" rid="bibr21-0003319711409741">21</xref></sup> Chilean<sup><xref ref-type="bibr" rid="bibr20-0003319711409741">20</xref></sup> populations, and from a pilot study in Poland.<sup><xref ref-type="bibr" rid="bibr41-0003319711409741">41</xref></sup></p>
<p>Inconsistent results related to the role of eNOS G894T polymorphism as a risk factor for CAD could be attributed to different frequency of eNOS alleles in various populations, gene–gene and gene–environment interactions and inadequate sample size.<sup><xref ref-type="bibr" rid="bibr20-0003319711409741">20</xref></sup></p>
<p>We found higher levels of LDL-C and TG in CAD patient carriers for T allele compared to those carriers of G allele. The study by Pereira et al<sup><xref ref-type="bibr" rid="bibr42-0003319711409741">42</xref></sup> demonstrated that eNOS G894T polymorphism modulate blood pressure through an interaction with lipid levels. They suggested that decrease in NO bioavailability is a major mechanism by which hypercholesterolemia may stimulate elevation of blood pressure. In patients with hypercholesterolemia oxidized LDL-C downregulates endothelial NOS expression. Also elevation of oxygen-free radical production by endothelium in the presence of hypercholesterolemia degrade NO molecules rapidly .<sup>
<xref ref-type="bibr" rid="bibr42-0003319711409741">42</xref>
</sup>
</p>
<p>Briefly, our results indicated the significantly higher frequency of eNOS 894T allele among CAD patients with and without diabetes compared to controls and an association between this polymorphism with CAD. We observed 2.15 times increased risk of CAD in the presence of T allele of eNOS in the population of Western Iran.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was financially supported by a grant from Vice Chancellor for Research of Kermanshah University of Medical Sciences, Kermanshah, Iran.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711409741">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="financial-disclosure" id="fn2-0003319711409741">
<p>The author(s) received no financial support for the research and/or authorship of this article</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711409741">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatmi</surname>
<given-names>ZN</given-names>
</name>
<name>
<surname>Tahvildari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gafarzadeh Motlag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sabouri Kashani</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Prevalence of coronary artery disease risk factors in Iran: a population based survey</article-title>. <source>BMC Cardivasc Dis</source>. <year>2007</year>;<volume>7</volume>:<fpage>32</fpage>.</citation>
</ref>
<ref id="bibr2-0003319711409741">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaisi-Raygani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rahimi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nomani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tavilani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pourmotabbed</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>The presence of apolipoprotein ϵ4 and ϵ2 alleles augments the risk of coronary artery disease in type 2 diabetic patients</article-title>. <source>Clin Biochem</source>. <year>2007</year>;<volume>40</volume>(<issue>15</issue>):<fpage>1150</fpage>–<lpage>1156</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711409741">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zintzaras</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Papathanasiou</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Stefanidis</surname>
<given-names>I.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis</article-title>. <source>Genet Med</source>. <year>2009</year>;<volume>11</volume>(<issue>10</issue>):<fpage>695</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711409741">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kajiyama</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Endothelial nitric oxide synthase gene is positively associated with essential hypertension</article-title>. <source>Hypertension</source>. <year>1998</year>;<volume>32</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711409741">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colombo</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Andreassi</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Paradossi</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298Asp polymorphism) to the presence, extent and severity of coronary artery disease</article-title>. <source>Heart</source>. <year>2002</year>;<volume>87</volume>(<issue>6</issue>):<fpage>525</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711409741">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lopez-Ridaura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>FB.</given-names>
</name>
</person-group> <article-title>Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among U.S. diabetic men</article-title>. <source>Diabetes</source>. <year>2006</year>;<volume>55</volume>(<issue>7</issue>):<fpage>2140</fpage>–<lpage>2147</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711409741">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesauro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Rogliani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2000</year>;<volume>97</volume>(<issue>6</issue>):<fpage>2832</fpage>–<lpage>2835</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711409741">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hingorani</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Fatibene</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk factor for coronary artery disease in the UK</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>14</issue>):<fpage>1515</fpage>–<lpage>1520</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711409741">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimasaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yasue</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1506</fpage>–<lpage>1510</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711409741">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamemoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Association of the Glu298Asp polymorphism of the eNOS gene with ischemic heart disease in Japanese diabetic subjects</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2008</year>;<volume>80</volume>(<issue>2</issue>):<fpage>275</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711409741">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HI.</given-names>
</name>
</person-group> <article-title>Analysis of endothelial nitric oxide synthase gene polymorphisms with cardiovascular disease in eastern Taiwan</article-title>. <source>Chin J Physiol</source>. <year>2008</year>;<volume>51</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711409741">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cam</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Sekuri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tengiz</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population</article-title>. <source>Thrombosis Res</source>. <year>2005</year>;<volume>116</volume>(<issue>4</issue>):<fpage>287</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711409741">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berdeli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sekuri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sirri Cam</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between the eNOS (Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population</article-title>. <source>Clin Chim Acta</source>. <year>2005</year>;<volume>351</volume>(<issue>1-2</issue>):<fpage>87</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711409741">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerkeni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Addad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chauffert</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease</article-title>. <source>Clin Chem</source>. <year>2006</year>;<volume>52</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711409741">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Motawi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shaker</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Taha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sedrak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nabil</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide synthase and angiotensinogen gene polymorphism in coronary artery diseases in Egypt</article-title>. <source>Angiology</source>. <year>2011</year>;<volume>62</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711409741">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szabo</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Kunstar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Acsady</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Methylenetetrahydrofolate reductase and nitric oxide synthase polymorphism in patients with atherosclerosis and diabetes</article-title>. <source>Pathol Oncol Res</source>. <year>2009</year>;<volume>15</volume>(<issue>4</issue>):<fpage>631</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711409741">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brscic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bergerone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gagnor</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up</article-title>. <source>Am Heart J</source>. <year>2000</year>;<volume>139</volume>(<issue>6</issue>):<fpage>979</fpage>–<lpage>984</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711409741">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilcken</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XL.</given-names>
</name>
</person-group> <article-title>The Glu298Asp (894G→T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease</article-title>. <source>J Mol Med</source>. <year>1999</year>;<volume>77</volume>(<issue>6</issue>):<fpage>511</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711409741">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liyou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Simons</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Coronary artery disease is not associated with the E298D variant of the constitutive, endothelial nitric oxide synthase gene</article-title>. <source>Clin Genet</source>. <year>1998</year>;<volume>54</volume>(<issue>6</issue>):<fpage>528</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711409741">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaramillo</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Lanas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lanas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salazar</surname>
<given-names>LA.</given-names>
</name>
</person-group> <article-title>Polymorphisms of the NOS3 gene in Southern Chilean subjects with coronary artery disease and controls</article-title>. <source>Clin Chim Acta</source>. <year>2010</year>;<volume>411</volume>(<issue>3-4</issue>):<fpage>258</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711409741">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>SW</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of endothelial nitric oxide synthase gene polymorphisms (-786T→C, 4a4b, 894G→T) in Korean patients with coronary artery disease</article-title>. <source>Thrombosis Res</source>. <year>2007</year>;<volume>119</volume>(<issue>5</issue>):<fpage>579</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711409741">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sundaram</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Lack of association between Glu (298) Asp polymorphism of endothelial nitric oxide synthase (eNOS) gene and coronary artery disease in Tamilian population</article-title>. <source>Indian Heart J</source>. <year>2008</year>;<volume>60</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711409741">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasser</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Bevin</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>DE</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease</article-title>. <source>Am Heart J</source>. <year>2001</year>;<volume>142</volume>(<issue>4</issue>):<fpage>586</fpage>–<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711409741">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aras</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>NQ</given-names>
</name>
<name>
<surname>Bakanay</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Gulec</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide gene polymorphism (Glu298Asp) is not associated with coronary artery disease in Turkish population</article-title>. <source>Thromb Haemost</source>. <year>2002</year>;<volume>87</volume>(<issue>2</issue>):<fpage>347</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711409741">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrikopoulos</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Grammatopoulos</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Tzeis</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of the 894G→T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction</article-title>. <source>BMC Med Genet</source>. <year>2008</year>;<volume>9</volume>:<fpage>43</fpage>.</citation>
</ref>
<ref id="bibr26-0003319711409741">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jafari</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rahimi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Vaisi-Raygani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients</article-title>. <source>Mol Cell Biochem</source>. <year>2011;353(1-2):23-34</year>;</citation>
</ref>
<ref id="bibr27-0003319711409741">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Judkins</surname>
<given-names>MP</given-names>
</name>
</person-group>. <article-title>Selective coronary arteriography. I. A percutaneous transfemoral technique</article-title>. <source>Radiology</source>. <year>1967</year>;<volume>89</volume>(<issue>5</issue>):<fpage>815</fpage>–<lpage>824</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711409741">
<label>28</label>
<citation citation-type="book">
<collab collab-type="author">WHO Study Group Report of a WHO consultation</collab>. <source>Part 1. Diagnosis and Classification of Diabetes Mellitus</source>. <publisher-loc>Geneva</publisher-loc>:<publisher-name>World Health Organization</publisher-name>; <year>1999</year>.</citation>
</ref>
<ref id="bibr29-0003319711409741">
<label>29</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Old</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>DR.</given-names>
</name>
</person-group> <article-title>Gene analysis</article-title>. In:<person-group person-group-type="editor">
<name>
<surname>Weatherall</surname>
<given-names>DJ</given-names>
</name>
</person-group> (Ed.), <source>Methods in Hemotology</source>. <volume>Vol 6</volume>. <publisher-loc>The thalassemias</publisher-loc>. <publisher-name>Livingstone</publisher-name>; <year>1983</year>: <fpage>74</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711409741">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zintzaras</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches</article-title>. <source>J Clin Epidemiol</source>. <year>2008</year>;<volume>61</volume>(<issue>7</issue>):<fpage>634</fpage>–<lpage>645</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711409741">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilsborough</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Mamotte</surname>
<given-names>CDS</given-names>
</name>
<name>
<surname>van Bockxmeer</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>O’Driscoll</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RR.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function</article-title>. <source>Atherosclerosis</source>. <year>2003</year>;<volume>169</volume>(<issue>1</issue>):<fpage>131</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711409741">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casas</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bautista</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Humphries</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hingorani</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide synthase genotype and ischemic heart disease. Meta-analysis of 26 studies involving 23028 subjects</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>11</issue>):<fpage>1359</fpage>–<lpage>1365</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711409741">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>The endothelial nitric oxide synthase gene is associated with coronary artery disease: a meta-analysis</article-title>. <source>Cardiology</source>. <year>2010</year>;<volume>116</volume>(<issue>4</issue>):<fpage>271</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711409741">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gulec</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karabulut</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ozdemir</surname>
<given-names>AO</given-names>
</name>
<etal/>
</person-group>. <article-title>Glu298Asp polymorphism of the eNOS is associated with coronary collateral development</article-title>. <source>Atherosclerosis</source>. <year>2008</year>;<volume>198</volume>(<issue>2</issue>):<fpage>354</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711409741">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odeberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Rastam</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lindblad</surname>
<given-names>U.</given-names>
</name>
</person-group> <article-title>The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus</article-title>. <source>BMC Cardiovasc Dis</source>. <year>2008</year>;<volume>8</volume>:<fpage>36</fpage>.</citation>
</ref>
<ref id="bibr36-0003319711409741">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Fidge</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Gallon-Beaumier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kingwell</surname>
<given-names>BA.</given-names>
</name>
</person-group> <article-title>High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>101</volume>(<issue>18</issue>):<fpage>6999</fpage>–<lpage>7004</lpage>.</citation>
</ref>
<ref id="bibr37-0003319711409741">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nofer</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>van der Giet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toelle</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>HDL induces NO dependent vasorelaxation via the lysophospholipid receptor S1P3</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>113</volume>(<issue>4</issue>):<fpage>569</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr38-0003319711409741">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karvonen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kauma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kervinen</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotide artery atherosclerosis in a population-based cohort</article-title>. <source>J Intern Med</source>. <year>2002</year>;<volume>251</volume>(<issue>2</issue>):<fpage>102</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr39-0003319711409741">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagib El-Kilany</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Nayel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hazzaa</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Nitric oxide synthase gene G298 allele is it a marker for microvascular angina in hypertensive patients?</article-title> <source>Cardiovasc Radiation Med</source>. <year>2004</year>;<volume>5</volume>(<issue>3</issue>):<fpage>113</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr40-0003319711409741">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YH.</given-names>
</name>
</person-group> <article-title>Lack of association between the Glu298Asp variant of the endothelial nitric oxide synthase gene and the risk of coronary artery disease among Taiwanese</article-title>. <source>J Formos Med Assoc</source>. <year>2001</year>;<volume>100</volume>(<issue>11</issue>):<fpage>736</fpage>–<lpage>740</lpage>.</citation>
</ref>
<ref id="bibr41-0003319711409741">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gluba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Banach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rysz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Piotrowski</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fendler</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pietrucha</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A pilot study</article-title>. <source>Angiology</source>. <year>2009</year>;<volume>60</volume>(<issue>5</issue>):<fpage>588</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr42-0003319711409741">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sposito</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mota</surname>
<given-names>GF</given-names>
</name>
<etal/>
</person-group>. <article-title>Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: new evidence for a direct effect of lipids in arterial blood pressure</article-title>. <source>Atherosclerosis</source>. <year>2006</year>;<volume>184</volume>(<issue>1</issue>):<fpage>193</fpage>–<lpage>200</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>